11 February 2016
InFlectis BioScience announces that the European Commission has granted orphan drug designation to its drug candidate IFB-088, also known as Sephin1, for the treatment of Charcot-Marie-Tooth disease (CMT). This status provides specific incentives to InFlectis BioScience for the development of IFB-088, including assistance in the development of clinical protocols, royalties’ exemptions from EMA and an exclusive ten-year marketing period in European Union.